Sangamo Therapeutics has identified a shortcut to market for its Fabry disease candidate, aligning with the FDA on a pathway that could slash three years from the time to market and free it from the ...
TipRanks on MSN
Sangamo receives U.S. FDA Fast Track Designation to ST-503
Therapeutics announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation to ST-503, an ...
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback